EscharEx® Product Profile

MediWound Ltd. (NASDAQ: MDWD) is a fully integrated biopharmaceutical company focused on developing, manufacturing and commercializing novel products that address unmet clinical needs in the treatment of severe burns, and chronic and other hard-to-heal wounds.

WHAT IS EscharEx®?

EscharEx® is an innovative topical biological drug being developed for debridement of chronic and other hard-to-heal wounds. EscharEx® contains the same proteolytic enzyme technology as NexoBrid®, and thus supported by the data that served for NexoBrid's European marketing authorization, including pre-clinical, toxicology and manufacturing & control data. During the first Phase 2 feasibility study, EscharEx® demonstrated efficacy in debridement of chronic and other hard-to-heal wounds such as diabetic foot ulcers, venous leg ulcers, pressure sores and other post-surgical or post-trauma hard-to-heal wounds after few topical applications. The wealth of existing development data with our lead product, NexoBrid®, for debridement of severe burns, as well as clinical data from the Phase 2 feasibility study, decrease the developmental risk of EscharEx®.

CHRONIC WOUNDS MARKET

There is significant market opportunity for EscharEx® as more than 14 million people in Europe and the U.S. alone, suffer from chronic wounds. Chronic and other hard-to-heal wounds represent a $25 billion burden to the U.S. healthcare system each year. Unfortunately, the incidence of patients suffering from such chronic wound conditions is growing due to the overall aging of the population and a higher prevalence of obesity and diabetes, among other factors. There is a great unmet medical need to effectively debride such wounds in a non-surgical manner, as debriding the wound is a critical first step for healing and can provide better conditions to aid such patients and surgery is often challenging due to the co-morbidities that such aged and often diabetic patients suffer from.

MediWound believes that most advanced wound care healing therapies, including negative pressure wound therapy and skin substitutes, would be complementary rather than competitive to EscharEx®, as these therapies require a clean wound bed to effectively heal a wound, which EscharEx® could provide.

MediWound has recently completed a comprehensive market research study on EscharEx® in the US and EU that surveyed over 200 healthcare professionals. According to the study there are over a million patients with diabetic foot or venous leg ulcers in the US alone that undergo debridement.

The surveyed physicians indicate that a product having EscharEx® product profile would potentially be prescribed to a significant portion of this patient pool.

These findings were re-affirmed by the US advisory board, which is comprised of leading US medical, marketing and reimbursement experts that were convened to review and discuss the research report.



PORCINE MODEL RESULTS

In porcine model studies, conducted at the Lahav CRO, Israel, in 72 wound, EscharEx® demonstrated efficacy in debriding chronic wounds vs. placebo.

EscharEx®



Before



After

Placebo



Before



After

FIRST PHASE 2 RESULTS

A Phase 2 feasibility study with the proteolytic enzyme mixture for debridement of chronic wounds showed promising results. The results from 24 patients at two clinical sites in Israel demonstrated efficacy in debriding various wound etiologies such as DFUs, venous ulcers, pressure sores and other post-surgical or post-trauma hard-to-heal wounds.

Diabetic Foot Ulcer (3 months old)



Before



After 2nd application

Post traumatic (6 weeks old)



Before



After 4th application

Venus Ulcer (11 months old)



Before



After 1st application

Pressure Sore (4 months old)



Before



After 2nd application

MediWound's second Phase 2 clinical trial evaluating EscharEx® for the treatment of hard-to-heal wounds, has finished enrollment.

The study was a prospective, randomized, controlled, multi-center, assessor blinded Phase 2 study of 73 patients, conducted at fifteen clinical sites in Israel and Europe and evaluated the safety and efficacy of EscharEx® compared with gel vehicle for the treatment of a variety of chronic and hard-to-heal wounds, including a study group of diabetic foot ulcers (DFUs), a study group of venous legs ulcers (VLUs) and a study group of post-surgical or traumatic hard-to-heal wounds. The primary endpoint of the study assessed incidence of complete non-viable tissue removal (debridement) and the secondary endpoints assessed several parameters including wound bed preparation, wound healing and other additional efficacy and safety endpoints.

Top-line study data is expected around year-end 2015.

October 2015

Contacts:

Sharon Malka
Chief Financial & Operations Officer
MediWound Ltd.
ir@mediwound.co.il

Anne Marie Fields
Senior Vice President
LHA
212-838-3777
afields@lhai.com

MediWound Ltd.

To learn more about MediWound Ltd visit:
www.mediwound.com